Taking this into account, BTIG Research initiated its ImmunityBio Inc [IBRX] rating to a Buy in a research note published on January 10, 2025; the price target was $6. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who decreased its forecast for the stock in mid May from “an Overweight” to “a Neutral”. Jefferies began covering IBRX with “Buy” recommendation on August 03, 2022.
Price Performance Review of IBRX
On Friday, ImmunityBio Inc [NASDAQ:IBRX] saw its stock fall -3.29% to $2.94. Over the last five days, the stock has gained 21.49%. ImmunityBio Inc shares have risen nearly 14.84% since the year began. Nevertheless, the stocks have fallen -19.45% over the past one year. While a 52-week high of $10.53 was reached on 01/17/25, a 52-week low of $2.28 was recorded on 01/14/25. SMA at 50 days reached $3.86, while 200 days put it at $4.98.
Levels Of Support And Resistance For IBRX Stock
The 24-hour chart illustrates a support level at 2.81, which if violated will result in even more drops to 2.69. On the upside, there is a resistance level at 3.18. A further resistance level may holdings at 3.43. The Relative Strength Index (RSI) on the 14-day chart is 48.30, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.14, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 35.29%. Stochastics %K at 59.74% indicates the stock is a holding.
How much short interest is there in ImmunityBio Inc?
A steep rise in short interest was recorded in ImmunityBio Inc stocks on 2024-12-31, growing by 0.23 million shares to a total of 50.01 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 49.78 million shares. There was a rise of 0.45%, which implies that there is a positive sentiment for the stock.
